Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis

Genes and Development

Volumn 14, Issue 14, 2000, Pages 1797-1809

  Inoue, Kazushi ^a   Wen, Renren ^a   Rehg, Jerold E ^a   Adachi, Masashi ^a,b   Cleveland, John L ^a   Roussel, Martine F ^a   Sherr, Charles J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Mizuno Hospital   (Japan)

Author keywords

ARF; Cell senescence; DMP1; P53; Ras transformation; Tumor suppression

Indexed keywords

ARF PROTEIN; DMP1 PROTEIN; GENE PRODUCT; RAS PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; EMBRYO; FEMALE; FIBROBLAST; GENE FREQUENCY; GENETIC TRANSCRIPTION; MALE; MALIGNANT TRANSFORMATION; MOUSE; NEWBORN PERIOD; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR SUPPRESSOR GENE;

3T3 CELLS; AGE FACTORS; ANIMALS; CELL DIVISION; CELLS, CULTURED; DNA, COMPLEMENTARY; FEMALE; FIBROBLASTS; GENE LIBRARY; GENOTYPE; HETEROZYGOTE; HUMANS; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, GENETIC; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; PROTEINS; RAS PROTEINS; T-LYMPHOCYTES; TIME FACTORS; TISSUE DISTRIBUTION; TRANSCRIPTION FACTORS; TRANSFORMATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034661167     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Babcock, V.I. and Southam, C.M. 1965. Obstructive uropathy in laboratory mice. Proc. Soc. Exp. Biol. Med. 120: 580-581.
2. Barak, Y., Juven, T., Haffner, R., and Oren, M. 1993. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468.
3. ARF links pRB and p53. Nature 395: 124-125.
4. Bodner, S.M., Naeve, C.W., Rakestraw, K.M., Jones, B.C., Valentine, V.A., Valentine, M.B., Luthardt, F.W., Willman, C.L., Raimondi, S.C., Downing, J.R. et al. 1999. Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). Gene 229: 223-228.
5. ARF tumor suppressor. Genes & Dev. 12: 2434-2442.
6. Eischen, C.M., Weber, J.D., Roussel, M.F., Sherr, C.J., and Cleveland, J.L. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes & Dev. 13: 2658-2669.
7. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, E., Kinzler, K.W., and Vogelstein, B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
8. Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180.
9. Gaillard, E.T. 1999. Ureter, urinary bladder, and urethra. In Pathology of the mouse (ed. R.R. Maronpot, G. A. Boorman, and B.G. Gaul), pp. 234-258. Cache River Press, Vienna, Illinois.
10. Gannon, J.V., Greaves, R., Iggo, R., and Lane, D.P, 1990. Activating mutations in p53 produce a common conformational effect: A monoclonal antibody specific for the mutant form. EMBO J. 9: 1595-1602.
11. Giaccia, A.J. and Kastan, M.B. 1998. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes & Dev. 12: 2973-2983.
12. Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A., and Dean, D.C. 1999. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869.
13. Harvey, D.M. and Levine, A.J. 1991. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes & Dev. 5: 2375-2385.
14. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
15. Hirai, H. and Sherr, C.J. 1996. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol. Cell. Biol. 16: 6457-6467.
16. Honda, R., Tanaka, H., and Yasuda, H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27.
17. ARF with Mdm2 inhibits ubiquitin ligase activity of MDM2 for tumor suppressor p53. EMBO J. 18: 22-27.
18. Inoue, K. and Sherr, C.J. 1998. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol. Cell. Biol. 18: 1590-1600.
19. Inoue, K., Sherr, C.J., and Shapiro, L.H. 1998. Regulation of the CD13/Aminopeptidase N gene by DMP1, a transcription factor antagonized by D-type cyclins. J. Biol. Chem. 273: 29188-29194.
20. Inoue, K., Roussel, M.F., and Sherr, C.J. 1999. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc. Natl. Acad. Sci. 96: 3993-3998.
21. Jacobs, J.J.L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., and van Lohuizen, M. 1999. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes & Dev. 13: 2678-2690.
22. ARF. Cell 91: 649-659.
23. Kamijo, T., Weber, J.D., Zambetti, G., Zindy, F., Roussel, M.F., and Sherr, C.J. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. 95: 8292-8297.
24. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D.H., and Sherr, C.J. 1999. Tumor Spectrum in ARF-deficient mice. Cancer Res. 59: 2217-2222.
25. Kastan, M.B., Zhan, Q., El-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., Vogelstein, B., and Fornace, A.J., Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
26. ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc. Natl. Acad. Sci. 97: 3266-3271.
27. Ko, L.J. and Prives, C. 1996. p53: Puzzle and paradigm. Genes & Dev. 10: 1054-1072.
28. Kubbutat, M.H., Jones, S.N., and Vousden, K.H. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
29. Land, H., Parada, L.F., and Weinberg, R.A. 1983. Cellular oncogenes and multistep carcinogenesis. Science 222: 771-778.
30. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
31. Lloyd, A.C., Obermuller, F., Staddon, S., Barth, C.F., McMahon, M., and Land, H. 1997. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes & Dev. 11: 663-667.
32. Maestro, R., Dei Tos, A.P., Hamamori, Y., Krasnokutky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D.H., and Hannon, G.J. 1999. Twist is a potential oncogene that inhibits apoptosis. Genes & Dev. 13: 2207-2217.
33. Midgley, C.A. and Lane, D.P. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189.
34. Miyashita, T. and Reed, J.C. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
35. Momand, J., Zambetti, G.P., Olson, D.C., George, D., and Levine, A.J. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
36. Nevins, J.R. 1998. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 9: 585-593.
37. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W., and Vogelstein, B. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860.
38. ARF links the tumour suppressor p53 to ras. Nature 395: 125-126.
39. Pantoja, C. and Serrano, M. 1999. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 18: 4974-4982.
40. Pattengale, P.K. and Firth, C.H. 1986. Contributions of recent research to the classification of spontaneous lymphoid neoplasms in mice. Crit. Rev. Toxicol. 16: 185-212.
41. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
42. Prives, C. 1998. Signaling to p53: Breaking the MDM2-p53 circuit. Cell 95: 5-8.
43. Quelle, D.E., Zindy, F., Ashmun, R.A., and Sherr, C.J. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
44. Quintanilla, M., Brown, K., Ramsden, M., and Balmain, A. 1986. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80.
45. Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sci. 95: 13194-13199.
46. Robertson, K.D. and Jones, P.A. 1998. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wildtype p53. Mol. Cell. Biol. 18: 6457-6473.
47. Roth, J., Dobbelstein, M., Freedman, D., Shenk, T., and Levine, A.J. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554-564.
48. Roussel, M.F., Dull, T.J., Rettenmier, C.W., Ralph, P., Ullrich, A., and Sherr, C.J. 1987. Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature 325: 549-552.
49. INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta Rev. Cancer 1378: F115-F177.
50. Ruley, H.E. 1983. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 304: 602-606.
51. Schmitt, C.A., McCurrach, M.E., de Stanchina, E., Wallace-Brodeur, R.R., and Lowe, S.W. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes & Dev. 13: 2670-2677.
52. Serrano, M., Hannon, G.J., and Beach, D. 1993. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
53. Serrano, M., Lee, R-W., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
54. INK4a. Cell 88: 593-602.
55. Sewing, A., Wiseman, B., Lloyd, A.C., and Land, H. 1997. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17: 5588-5597.
56. Sherr, C.J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes & Dev. 12: 2984-2991.
57. Slansky, J.E. and Farnham, P.J. 1996. Introduction to the E2F family: Protein structure and gene regulation. Curr. Top. Microbiol. Immunol. 208: 1-30.
58. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001-5014.
59. ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. 96: 6937-6941.
60. Todaro, G.J. and Green, H. 1963. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17: 299-313.
61. Weber, J.D., Taylor, L.J., Roussel, M.F., Sherr, C.J., and Bar-Sagi, D. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1: 20-26.
62. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
63. Wu, X., Bayle, J.H., Olson, D., and Levine, A.J. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes & Dev. 7: 1126-1132.
64. Yewdell, J.W., Gannon, J.V., and Lane, D.P. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59: 444-452.
65. Zhang, Y., Xiong, Y., and Yarbrough, W.G. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppressor pathways. Cell 92: 725-734.
66. Zhu, J., Woods, D., McMahon, M., and Bishop, J.M. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes & Dev. 12: 2997-3007.
67. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203-211.
68. Zindy, F., Eischen, C.M., Randle, D., Kamijo, T., Cleveland, J.L., Sherr, C.J., and Roussel, M.F. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & Dev. 12: 2424-2433.
69. Zindy, F., Van Deursen, J., Grosveld, G., Sherr, C.J., and Roussel, M.F. 1999. Testicular Atrophy in INK4d-deficient Mice. Mol. Cell. Biol. 20: 372-378.